Please login to the form below

azacitidine

This page shows the latest azacitidine news and features for those working in and with pharma, biotech and healthcare.

AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML

Researchers found that Venclyxto (venetoclax) – known as Venclexta in the US – in combination with azacitidine extended overall survival (OS) compared to the azacitidine plus placebo arm. ... The safety profile of the treatment was found to be

Latest news

Givlaari, Rybelsus lead crowded CHMP recommendations

a host of other indications, as well as azacitidine betapharm (azacytidine) and azacitidine Mylan (azacitidine) for the treatment of a number of blood cancers.
BMS’ oral maintenance therapy boosts survival in AML patients

CC-486 is an oral version of Celgene’s already-marketed chemotherapy Vidaza (azacitidine), which is administered intravenously – it had been a top-selling product for the company, before being hit
Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

Regulatory filings expected in first half of 2020. Celgene’s oral version of acute myeloid leukaemia (AML) chemotherapy azacitidine has hit the target in a phase 3 trial, setting up regulatory ... The formulation – known as CC-486 – is an
Tecentriq’s triple negative breast cancer use among key CHMP nods

The drug gained FDA approval in December 2017. Celgene also received a positive opinion for azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloidleukaemia.
Dutch biotech Argenx claims $1.8bn licensing deal with J&J

It is being given in combination with Celgene’s Vidaza (azacitidine) and will look at escalating doses of Argenx’ drug, given intravenously, with a standard dose of Vidaza.

More from news
Approximately 2 fully matching, plus 19 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

The FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethylating agent (azacitidine or decitabine) for the exact same indication – adding to the options for this patient

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....